Cargando…

Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives

Rhabdomyosarcomas (RMS) are a heterogeneous group of tumors that share features of skeletal myogenesis and represent the most common pediatric soft tissue sarcoma. Even though significant advances have been achieved in RMS treatment, prognosis remains very poor for many patients. Several elements of...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Ana Sofia, Olmos, David, Missiaglia, Edoardo, Shipley, Janet
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061277/
https://www.ncbi.nlm.nih.gov/pubmed/21437217
http://dx.doi.org/10.1155/2011/209736
_version_ 1782200588715425792
author Martins, Ana Sofia
Olmos, David
Missiaglia, Edoardo
Shipley, Janet
author_facet Martins, Ana Sofia
Olmos, David
Missiaglia, Edoardo
Shipley, Janet
author_sort Martins, Ana Sofia
collection PubMed
description Rhabdomyosarcomas (RMS) are a heterogeneous group of tumors that share features of skeletal myogenesis and represent the most common pediatric soft tissue sarcoma. Even though significant advances have been achieved in RMS treatment, prognosis remains very poor for many patients. Several elements of the Insulin-like Growth Factor (IGF) pathway are involved in sarcomas, including RMS. The IGF2 ligand is highly expressed in most, if not all, RMS, and frequent overexpression of the receptor IGF1R is also found. This is confirmed here through mining expression profiling data of a large series of RMS samples. IGF signaling is implicated in the genesis, growth, proliferation, and metastasis of RMS. Blockade of this pathway is therefore a potential therapeutic strategy for the treatment of RMS. In this paper we examine the biological rationale for targeting the IGF pathway in RMS as well as the current associated preclinical and clinical experience.
format Text
id pubmed-3061277
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30612772011-03-24 Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives Martins, Ana Sofia Olmos, David Missiaglia, Edoardo Shipley, Janet Sarcoma Review Article Rhabdomyosarcomas (RMS) are a heterogeneous group of tumors that share features of skeletal myogenesis and represent the most common pediatric soft tissue sarcoma. Even though significant advances have been achieved in RMS treatment, prognosis remains very poor for many patients. Several elements of the Insulin-like Growth Factor (IGF) pathway are involved in sarcomas, including RMS. The IGF2 ligand is highly expressed in most, if not all, RMS, and frequent overexpression of the receptor IGF1R is also found. This is confirmed here through mining expression profiling data of a large series of RMS samples. IGF signaling is implicated in the genesis, growth, proliferation, and metastasis of RMS. Blockade of this pathway is therefore a potential therapeutic strategy for the treatment of RMS. In this paper we examine the biological rationale for targeting the IGF pathway in RMS as well as the current associated preclinical and clinical experience. Hindawi Publishing Corporation 2011 2011-03-03 /pmc/articles/PMC3061277/ /pubmed/21437217 http://dx.doi.org/10.1155/2011/209736 Text en Copyright © 2011 Ana Sofia Martins et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Martins, Ana Sofia
Olmos, David
Missiaglia, Edoardo
Shipley, Janet
Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives
title Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives
title_full Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives
title_fullStr Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives
title_full_unstemmed Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives
title_short Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives
title_sort targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061277/
https://www.ncbi.nlm.nih.gov/pubmed/21437217
http://dx.doi.org/10.1155/2011/209736
work_keys_str_mv AT martinsanasofia targetingtheinsulinlikegrowthfactorpathwayinrhabdomyosarcomasrationaleandfutureperspectives
AT olmosdavid targetingtheinsulinlikegrowthfactorpathwayinrhabdomyosarcomasrationaleandfutureperspectives
AT missiagliaedoardo targetingtheinsulinlikegrowthfactorpathwayinrhabdomyosarcomasrationaleandfutureperspectives
AT shipleyjanet targetingtheinsulinlikegrowthfactorpathwayinrhabdomyosarcomasrationaleandfutureperspectives